Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190
Leerink Partners analyst Puneet Souda maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $160 to $190.
Share
Why It Matters
An analyst who covers biotech companies raised their price target for Twist Bioscience higher. This suggests the analyst thinks the company's future looks stronger than before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.